AIA Group Ltd Increases Position in Illumina, Inc. (NASDAQ:ILMN)

AIA Group Ltd increased its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 13.1% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 65,214 shares of the life sciences company's stock after purchasing an additional 7,547 shares during the quarter. AIA Group Ltd's holdings in Illumina were worth $8,505,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the company. UMB Bank n.a. grew its position in shares of Illumina by 7.0% in the second quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company's stock valued at $140,000 after purchasing an additional 88 shares during the last quarter. Integrated Advisors Network LLC grew its stake in Illumina by 2.0% during the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company's stock worth $585,000 after buying an additional 90 shares during the period. Texas Permanent School Fund Corp raised its stake in shares of Illumina by 0.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 32,818 shares of the life sciences company's stock valued at $4,507,000 after acquiring an additional 114 shares during the period. Institute for Wealth Management LLC. boosted its position in Illumina by 4.6% during the 2nd quarter. Institute for Wealth Management LLC. now owns 2,728 shares of the life sciences company's stock worth $285,000 after purchasing an additional 119 shares during the period. Finally, Massmutual Trust Co. FSB ADV increased its holdings in Illumina by 65.1% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock valued at $56,000 after purchasing an additional 168 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ILMN shares. StockNews.com assumed coverage on Illumina in a report on Thursday, August 29th. They set a "buy" rating on the stock. Daiwa America upgraded shares of Illumina to a "strong-buy" rating in a research report on Friday, August 16th. Citigroup boosted their price objective on shares of Illumina from $155.00 to $190.00 and gave the company a "buy" rating in a research report on Tuesday. Hsbc Global Res upgraded Illumina from a "hold" rating to a "strong-buy" rating and set a $180.00 price target for the company in a report on Thursday, October 17th. Finally, HSBC raised shares of Illumina from a "hold" rating to a "buy" rating and set a $180.00 price objective for the company in a report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Illumina presently has a consensus rating of "Moderate Buy" and a consensus price target of $162.18.

Illumina Price Performance

NASDAQ:ILMN traded down $5.03 during mid-day trading on Friday, reaching $150.12. The stock had a trading volume of 1,332,607 shares, compared to its average volume of 2,005,153. The stock has a market capitalization of $23.91 billion, a PE ratio of -15.58 and a beta of 1.13. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a 50-day simple moving average of $137.27 and a two-hundred day simple moving average of $123.12. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 6.36%. The company's revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.33 EPS. On average, equities analysts anticipate that Illumina, Inc. will post 3.62 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.